B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2024-07-12Clinical Trial Update: Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy [Phase 1, Phase 2]
A Phase 1/Phase 2 trial evaluating Interferon-Beta-1a (FP-1201) to prevent toxicities after CD19-directed CAR T-cell therapy has been withdr…
-
CLINICAL_TRIALS research · 2024-07-11Clinical Trial Update: A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.
This clinical trial update describes a study evaluating the efficacy and safety of glofitamab in combination with salvage therapy for relaps…
-
CLINICAL_TRIALS trial_result · 2024-06-20Clinical Trial Update: Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial of Capivasertib in relapsed or refractory B-cell non-Hodgkin lymphoma has completed, with results posted in June 2024.
-
CLINICAL_TRIALS trial_result · 2024-05-17Clinical Trial Update: Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL [Phase 2]
Phase 2 study evaluating Debio 1562 in combination with Rituximab for relapsed/refractory Diffuse Large B-Cell Lymphoma and other B-cell non…
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia [Phase 1, Phase 2]
Clinical trial update for allogeneic CARCIK-CD19 in adults and children with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia; Ph…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma [Phase 1]
A Phase I safety, pharmacokinetic and pharmacodynamic study of KW-2478 in patients with multiple myeloma, chronic lymphocytic leukemia, or B…
-
CLINICAL_TRIALS withdrawal · 2024-04-25Clinical Trial Update: CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL [Phase 1]
A Phase 1 trial investigating CpG-STAT3 siRNA CAS3/SS3 with localized radiation for relapsed/refractory B-cell non-Hodgkin lymphomas has bee…
-
CLINICAL_TRIALS trial_result · 2024-04-22Clinical Trial Update: Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation [EARLY_Phase 1]
A phase 1 pilot trial evaluating pembrolizumab for relapse after allogeneic stem cell transplantation in patients with classical Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2023-07-06Clinical Trial Update: TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL [Phase 1, Phase 2]
Clinical trial update for TRAC locus-inserted CD19-targeting STAR-T cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma (Phase 1…
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide [Phase 1, Phase 2]
Trial update for an injectable IMM0306 in combination with lenalidomide for B-cell non-Hodgkin's lymphoma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2023-05-22Clinical Trial Update: A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. [Phase 1, Phase 2]
A safety, tolerability, pharmacokinetics and efficacy study of GB261 in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is in P…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating acalabrutinib with rituximab and lenalidomide in relapsed/refractory B-cell non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update for bortezomib and gemcitabine in relapsed B-cell non-Hodgkin lymphoma (Phase 1/Phase 2) completed with results posted…
-
CLINICAL_TRIALS trial_result · 2023-02-24Clinical Trial Update: Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells [Phase 2]
A Phase 2 clinical trial assessing the safety and efficacy of a regimen combining BTK inhibitor with anti-CD19 CAR-T cells for relapsed/refr…
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial investigating XPO-1 inhibitors in combination with CAR-T cells for relapsed/refractory B-cell non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL [Phase 1, Phase 2]
Dose-escalation early-stage trial assessing safety of PBCAR20A in relapsed/refractory Non-Hodgkin's Lymphoma and relapsed/refractory Chronic…
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan [Phase 2]
Phase II trial evaluating allogeneic hematopoietic cell transplantation for B-cell non-Hodgkin lymphoma using Zevalin, fludarabine, and melp…
-
CLINICAL_TRIALS trial_result · 2022-08-22Clinical Trial Update: Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China [Phase 2]
A Phase 2 safety analysis evaluating intravenous rapid infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma conducted in …
-
CLINICAL_TRIALS trial_result · 2022-05-09Clinical Trial Update: A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma [Phase 1, Phase 2]
A pharmacokinetic and pharmacodynamic study comparing HLX01 and Rituximab in CD20-positive B-cell lymphoma completed Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2022-01-27Clinical Trial Update: A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 1, Phase 2]
Phase I/II study investigating CM355 in relapsed or refractory B-cell non-Hodgkin's lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Phase 3 clinical trial update investigating zanubrutinib with rituximab and/or combination chemotherapy for newly diagnosed aggressive B-cel…
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Phase 3 trial update evaluating orelabrutinib with rituximab and combination chemotherapy for newly diagnosed aggressive B-cell non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2021-09-28Clinical Trial Update: SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial update for SHR1459 in combination with YY-20394 in recurrent and refractory B-cell non-Hodgkin's lymphoma is listed, with stat…
-
CLINICAL_TRIALS trial_result · 2021-06-24Clinical Trial Update: CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma [Phase 2]
Phase 2 trial evaluating CD8+ memory T-cells as consolidative therapy after donor non-myeloablative hematopoietic cell transplant in leukemi…
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating high-dose Y-90 ibritumomab tiuxetan added to reduced-intensity allogeneic stem cell transplant for relapsed or refr…